Natera announced statistically significant improvements in disease-free and overall survival for Signatera-positive muscle-invasive bladder cancer patients treated with Genentech's Tecentriq in the Phase III IMvigor011 trial. The Signatera circulating tumor DNA (ctDNA) test identifies minimal residual disease post-surgery, enabling better patient stratification for adjuvant therapy decisions. An FDA premarket application for Signatera as a companion diagnostic is in preparation. Lead investigator Thomas Powles emphasized the potential shift in treatment paradigms for adjuvant therapy based on molecular relapse detection, reflecting a precision medicine approach to bladder cancer management.